The Impact of Everolimus and Radiation Therapy on Pulmonary Fibrosis

Basit Öğe Kaydı
dc.authoridDaliparty, Vasudev Malik/0000-0002-8375-0514
dc.authoridKilickap, Saadettin/0000-0003-1637-7390
dc.authoridOZGUVEN, YILDIRAY/0000-0003-4060-2164
dc.authorideren, mehmet fuat/0000-0002-6531-978X
dc.contributor.authorEren, Mehmet Fuat
dc.contributor.authorEren, Ayfer Ay
dc.contributor.authorSayan, Mutlay
dc.contributor.authorYucel, Birsen
dc.contributor.authorElagoz, Sahende
dc.contributor.authorOzguven, Yildiray
dc.contributor.authorVergalasova, Irina
dc.date.accessioned2024-10-26T18:11:34Z
dc.date.available2024-10-26T18:11:34Z
dc.date.issued2020
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractBackground and objectives:Everolimus (EVE) is a mammalian target of the rapamycin (mTOR) inhibitor that is widely used in cancer patients. Pulmonary toxicity, usually manifesting as interstitial pneumonitis, is a serious adverse effect of this drug. Radiation therapy, which is often administered in conjunction with chemotherapy for synergistic effects, also causes pulmonary fibrosis. In view of pulmonary damage development in these two forms of cancer treatment, we have examined the effect of EVE administration individually, in combination with radiation given in varying sequences, and its relation to the extent of pulmonary damage.Materials and Methods:We performed an experimental study in albino rats, which were randomized into five groups: (1) control group, (2) EVE alone, (3) EVE 22 h after radiation, (4) EVE 2 h after irradiation, and (5) only radiation. Sixteen weeks after thoracic irradiation, rat lung tissue samples were examined under light microscopy, and the extent of pulmonary damage was estimated. After this, we calculated median fibrosis scores in each group.Results:The highest fibrosis score was noted in Group 4. Among the five groups, the control group had a significantly lower median fibrosis score compared to the others. When the median fibrosis score of the group that received concurrent EVE with radiation therapy (RT) (Group 4) was compared with that of the control group, the difference was statistically significant (p= 0.0022). However, no significant differences were achieved among the study groups that received EVE only or RT only, whether concurrently or sequentially (p> 0.05).Conclusion:EVE is an effective treatment option for the management of several malignancies and is often combined with other therapies, such as radiation, for a more efficient response. However, an increased risk of pulmonary fibrosis should also be anticipated when these two modalities are combined, as they both can cause pulmonary damage, especially when administered concurrently.
dc.identifier.doi10.3390/medicina56070348
dc.identifier.issn1010-660X
dc.identifier.issn1648-9144
dc.identifier.issue7
dc.identifier.pmid32668776
dc.identifier.scopus2-s2.0-85087835966
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.3390/medicina56070348
dc.identifier.urihttps://hdl.handle.net/20.500.12418/30738
dc.identifier.volume56
dc.identifier.wosWOS:000557649500001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMdpi
dc.relation.ispartofMedicina-Lithuania
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectradiation therapy
dc.subjectrat
dc.subjecteverolimus
dc.subjectpneumonitis
dc.subjectpulmonary fibrosis
dc.titleThe Impact of Everolimus and Radiation Therapy on Pulmonary Fibrosis
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu